Dezamizumab is a monoclonal antibody designed to target serum amyloid P component (SAP), a protein that accumulates in amyloid deposits associated with systemic amyloidosis. By binding specifically to SAP, dezamizumab facilitates the clearance of these deposits through immune-mediated mechanisms. It has been investigated for the treatment of amyloidosis, particularly in cases where amyloid buildup affects vital organs such as the heart, kidneys, and liver. The antibody helps disrupt the stability of amyloid fibrils, potentially slowing disease progression and improving organ function. Due to its targeted action, dezamizumab represents a disease-modifying approach rather than symptomatic relief, offering potential in both primary and secondary forms of amyloidosis. It has been used in clinical research settings to evaluate its efficacy in reducing amyloid burden and improving patient outcomes.